NEWS & EVENTS

Catalent today announced a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeted at COVID-19.

Catalent today welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab.

Arcturus and Catalent today announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate, intended to protect against the SARS-CoV-2 coronavirus.

Catalent today announced the appointment of Manja Boerman, Ph.D., to the role of President, Cell & Gene Therapy. In this new role, Dr. Boerman will lead all of Catalent’s cell & gene therapy businesses worldwide.

Catalent today announced a collaboration with Johnson & Johnson for large-scale commercial manufacturing at its facility in Bloomington, Indiana of Johnson & Johnson’s lead vaccine candidate for COVID-19.

Catalent today announced that two of its experts will present at upcoming virtual industry conferences: CPhI North America Webinar Week; and Clinical Trial Supply 2020 – A Virtual Experience.

Catalent today announced the completion of its $14 million expansion to increase the biologics packaging capabilities and capacity at its Bloomington, Indiana facility.

Catalent today published its first Corporate Responsibility (CR) Report, covering fiscal year 2019. The report brings a new level transparency and ambition to a wide range of ESG topics related to Catalent’s business.

Catalent today announced that it has been recognized by the Royal Society for the Prevention of Accidents for its health and safety practices, achieving a silver award for a second consecutive year.